Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

ESMO 2025 | Lenvatinib + pembrolizumab after immunotherapy: PFS benefits and toxicity insights

Andrew Hahn • 17 Oct 2025

ESMO 2025

CONTACT-303 LenCabo

Andrew Hahn, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses treatment options for patients who progress on first-line immunotherapy, highlighting lenvatinib plus pembrolizumab as an effective choice. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.